|
|
||||||||
1 Departments of Research and Medicine, Saint Francis Hospital and Medical Center, Hartford 06105; and 2 The University of Connecticut School of Medicine, Farmington, Connecticut 06030
| |
ABSTRACT |
|---|
|
|
|---|
Hepatocyte growth factor/scatter factor (HGF/SF) is expressed by osteoblasts and has important effects on repair and bone remodeling. Because glucocorticoids regulate these two functions, we tested the effects of cortisol on the expression of HGF/SF and c-met, the protooncogene encoding the HGF/SF receptor, in cultures of osteoblast-enriched cells from 22-day fetal rat calvariae (Ob cells). Cortisol decreased HGF/SF mRNA levels and diminished the induction of HGF/SF transcripts by fibroblast growth factor-2 (FGF-2) and platelet-derived growth factor BB (PDGF BB). Cortisol also decreased FGF-2 and PDGF BB-induced HGF/SF mRNA and polypeptide levels in MC3T3 cells. In contrast, cortisol enhanced the expression of c-met transcripts in Ob cells. Cortisol did not modify the half-life of HGF/SF or of c-met mRNA in transcriptionally arrested cells, and it increased the rate of transcription of c-met. In conclusion, cortisol decreases HGF/SF transcripts in Ob cells and enhances c-met expression transcriptionally. The effects of cortisol on HGF/SF could be relevant to its inhibitory actions on bone formation and repair.
skeletal tissue; glucocorticoids; wound healing; fractures; growth factors
| |
INTRODUCTION |
|---|
|
|
|---|
GLUCOCORTICOIDS HAVE MARKED EFFECTS on the skeleton, and prolonged exposure to excessive amounts of these corticosteroids results in osteoporosis (8, 13). Glucocorticoids have complex actions on bone formation and resorption, although their inhibitory effects on bone formation appear central to the bone loss observed after glucocorticoid excess (8, 13). Glucocorticoids decrease the pool of available osteoblasts and cause osteoblast apoptosis (44). In addition, they have direct actions on specific genes expressed by the osteoblast and regulate the synthesis and activity of locally produced growth factors (8, 13). For example, glucocorticoids have opposite effects to those of insulin-like growth factor (IGF) I on bone formation and inhibit the transcription of the growth factor in osteoblasts (12, 24). This would suggest a possible role of IGF-I and other growth factors in mediating selected actions of glucocorticoids in bone.
Hepatocyte growth factor/scatter factor (HGF/SF) is a polypeptide
composed of a 69-kDa
-chain with four krinkle domains and a 34-kDa
-chain with a serum protease-like sequence linked by disulfide bonds
(31, 38). HGF/SF stimulates mitogenesis in hepatic and extrahepatic
cells, enhances angiogenesis, and plays a role in repair in liver and
kidney, and possibly in other tissues (26, 33, 36, 38, 42). HGF/SF
signals via the product of the protooncogene c-met, a tyrosine
kinase-activated receptor (5, 32). HGF/SF and c-met are expressed by
mesenchymal cells, osteoblasts, and osteoclasts (4, 21). HGF/SF is
mitogenic for cells of the osteoblastic and osteoclastic lineage, and
its synthesis by the osteoblast is enhanced by growth factors with a
role in wound and fracture repair (4, 21). Therefore, it was postulated
to have a function in bone remodeling and repair (21).
Glucocorticoids not only cause a decrease in bone formation, but they also alter wound and possibly fracture healing (3). Although this may be the result of direct actions of glucocorticoids on cellular events at the wound or fracture site, it may involve alterations in the production or activity of locally produced factors, such as HGF/SF. In an initial effort to explore a possible role of HGF/SF as a mediator of glucocorticoid action in bone, in the present study we examined the effects of cortisol on the expression of HGF/SF and c-met in cultures of osteoblast-enriched cells from 22-day fetal rat calvariae (Ob cells).
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Culture technique.
The culture method used was described in detail previously (29).
Parietal bones were obtained from 22-day-old fetal rats immediately
after the mothers were killed by blunt trauma to the nuchal area. The
project was approved by the Institutional Animal Care and Use Committee
of Saint Francis Hospital and Medical Center. Cells were obtained by
five sequential digestions of the parietal bone by use of bacterial
collagenase (CLS II, Worthington Biochemical, Freehold, NJ). Cell
populations harvested from the third to the fifth digestions were
cultured as a pool and were previously shown to have osteoblastic
characteristics (26). Ob cells were plated at a density of
8,000-12,000 cells/cm2 and cultured in a humidified
5% CO2 incubator at 37°C until reaching confluence
(~50,000 cells/cm2). Cells were cultured in DMEM (Life
Technologies, Grand Island, NY) supplemented with nonessential amino
acids, 20 mM HEPES, and 10% fetal bovine serum (FBS; Summit,
Biotechnology, Fort Collins, CO) and were grown to confluence. MC3T3
cells, an osteoblastic cell line created by Sudo et al. (39) and
derived from fetal mouse calvaria, were cultured in
-MEM (Life
Technologies) supplemented with 20 mM HEPES and 10% FBS under the same
conditions as Ob cells and grown to confluence (39). At confluence,
cells were transferred to serum-free medium for 20-24 h and
exposed to test or control medium in the absence of serum for 2-48
h, as indicated in the text and legends. In 48-h-treated cultures, the
medium was replaced after 24 h with fresh control or test solutions.
For nuclear run-on experiments, Ob cells were grown to subconfluence,
trypsinized, replated, grown to confluence, serum-deprived for
20-24 h, and exposed to test or control solutions for 2-24 h.
70°C. For nuclear run-on assays, nuclei were isolated by
Dounce homogenization. For protein levels, the culture medium was
collected in the presence of 0.1% polyoxyethylenesorbitan monolaureate
(Tween-20, Pierce Chemical, Rockford, IL), and assays were performed at
the completion of the culture.
Northern blot analysis.
Total cellular RNA was isolated using an RNeasy kit and following the
manufacturer's instructions (Qiagen, Chatsworth, CA). The RNA
recovered was quantitated by spectrometry, and equal amounts of RNA
from control or test samples were loaded on a formaldehyde agarose gel
after denaturation. The gel was stained with ethidium bromide to
visualize RNA standards and ribosomal RNA, documenting equal RNA
loading of the various experimental samples. The RNA was then blotted
onto Gene Screen Plus charged nylon (Du Pont, Wilmington, DE), and
uniformity of transfer was documented by revisualization of ribosomal
RNA. A 1.4-kb EcoR I restriction fragment of a rat HGF/SF cDNA
(kindly provided by T. Nakamura, Osaka, Japan) and a 4.0-kb Not
I restriction fragment of a mouse c-met cDNA (kindly provided by C. C. Lee, Bethesda, MD) were purified by agarose gel electrophoresis (25,
31). HGF/SF and c-met cDNAs were labeled with
[
-32P]deoxycytidine triphosphate (dCTP) and
[
-32P]deoxyadenosine triphosphate (dATP) (50 µCi each at a specific activity of 3,000 Ci/mmol; Du Pont) by use of
the random hexanucleotide primed second strand synthesis method (17).
Hybridizations were carried out at 42°C for 16-72 h, and
posthybridization washes were performed in 0.5× saline-sodium
citrate (SSC) at 65°C. The blots were stripped and rehybridized
with an
-32P-labeled 752-bp BamH I/Sph I
restriction fragment of the murine 18S cDNA (American Type Culture
Collection, Rockville, MD) under the conditions described, followed by
two posthybridization washes in 1× SSC at room temperature and
one wash in 0.1× SSC at 65°C. Unlabeled 18S cDNA was added in
excess to the
-32P-labeled probe before being added to
the hybridization mixture to ensure sufficient quantity of 18S cDNA to
bind to the 18S rRNA. The bound radioactive material was visualized by
autoradiography on Kodak X-AR5 film (Eastman Kodak, Rochester, NY)
employing Cronex Lightning Plus (Du Pont) or Biomax MS (Eastman Kodak)
intensifying screens. Relative hybridization levels were determined by
densitometry. Northern analyses shown are representative of three or
more cultures.
Nuclear run-on assay.
To examine changes in the rate of transcription, nuclei were isolated
by Dounce homogenization in Tris buffer containing 0.5% Nonidet P-40.
Nascent transcripts were labeled by incubation of nuclei in a reaction
buffer containing 500 µM each of adenosine, cytidine, and guanosine
triphosphates, 150 units RNasin (Promega, Madison, WI), and 250 µCi
[
32P]uridine triphosphate (UTP) (3,000 Ci/mM, Du Pont) (22). RNA was isolated by treatment with DNase I and
proteinase K, followed by phenol-chloroform extraction and ethanol
precipitation. Linearized plasmid DNA containing 1 µg each of cDNA
was immobilized onto GeneScreen Plus by slot blotting according to the
manufacturer's directions (Du Pont). Murine 18S cDNA was used to
estimate uniformity of counts applied to the membrane. Equal counts per
minute of [32P]RNA from each sample were
hybridized to cDNAs at 42°C for 72 h and washed in 1× SSC at
65°C for 30 min. Hybridized cDNAs were visualized by
autoradiography. Nuclear run-on assays were done twice.
HGF/SF immunoassay. An enzyme immunoassay (EIA) detection kit (Institute of Immunology, Tokyo, Japan) was used to measure immunoreactive rodent HGF/SF (2). Medium samples were cleared by centrifugation, and a 50-µl aliquot of the supernatant was dispensed in duplicate into a 96-well plate precoated with anti-rat HGF/SF mouse monoclonal antibody. HGF/SF standard solutions were provided by the manufacturer. After an overnight incubation at room temperature, the plate was washed and incubated with anti-rat HGF/SF rabbit polyclonal antibody followed by the addition of peroxidase-labeled goat anti-rabbit immunoglobulin. HGF/SF levels were detected by colorimetry after an enzymatic reaction using the peroxidase substrate o-phenylenediamine and measurement of the product with a microplate spectrophotometer at 490 nm. Data are expressed in nanograms of HGF/SF per milliliter of medium or nanograms per milligram of protein, determined by use of a Bio-Rad DC protein assay kit according to the manufacturer's instructions (Bio-Rad, Hercules, CA).
Statistical analysis. Data are expressed as means ± SE, and statistical differences for immunoreactive HGF/SF levels were determined by ANOVA and post hoc examination by Scheffé's test. Slopes of mRNA decay were analyzed by the method of Sokal and Rohlf (37).
| |
RESULTS |
|---|
|
|
|---|
Northern blot analysis of total RNA extracted from Ob cells revealed
HGF/SF transcripts of 6.3, 3.7, and 3.1 kb (Fig.
1). There was a time-dependent increase in
HGF/SF mRNA levels in serum-deprived confluent Ob cells cultured over a
2- to 48-h period. This increase was noted after 24 and 48 h, and it
was prevented by cortisol at 1 µM so that cortisol decreased HGF/SF
mRNA levels from a respective 24-h control value of 1.00 to a value of
0.6 ± 0.05 (SE; n = 13), and from a respective 48-h cortisol
value of 1.00 to a value of 0.3 ± 0.04 (n = 3), as
determined by densitometry (Fig. 1). The inhibitory effect of cortisol
on HGF/SF mRNA was dose dependent, and continuous treatment of Ob cells
with cortisol at 100 nM and 1 µM for 24 h decreased HGF/SF
transcripts from a control value of 1.00 to values of 0.7 ± 0.04 (SE; n = 7) and 0.6 ± 0.05 (n = 13) (Fig.
2).
|
|
Cortisol inhibited control and growth factor-induced expression
of HGF/SF. Confirming previous observations in MC3T3 cells, FGF-2
at 2 nM and PDGF BB at 3.3 nM for 24 h increased HGF/SF mRNA levels in
Ob cells, and cortisol at 1 µM for 24 h decreased the induction of
HGF/SF mRNA levels by the two growth factors (Fig.
3) (4). The constitutive expression of
HGF/SF in serum-deprived MC3T3 cells is minimal; therefore, FGF-2 and
PDGF BB tend to cause a more pronounced relative stimulatory effect on
HGF/SF in MC3T3 than in Ob cells compared with control untreated
cultures (Figs. 3 and 4). The stimulatory
effect of FGF-2 at 2 nM and PDGF BB at 3.3 nM in MC3T3 cells also was
opposed by cortisol at 1 µM for 24 h (Fig. 4).
|
|
The levels of immunoreactive HGF/SF in control untreated and
cortisol-treated Ob and MC3T3 cells were below the limit of detection of the assay, which is 0.4 ng/ml. Neither FGF-2 at 2 nM nor PDGF BB at
3.3 nM for 24 or 48 h caused a detectable increase in immunoreactive HGF/SF in Ob cells, so that the inhibitory effect of cortisol on
immunoreactive HGF/SF could not be tested in these cells. In contrast,
FGF-2 and PDGF BB increased HGF/SF polypeptide levels in MC3T3 cells
treated for 48 h, and the effect was opposed by cortisol (Table
1).
|
Northern blot analysis of total RNA extracted from confluent cultures
of Ob cells revealed a predominant c-met transcript of 8.6 kb (Fig.
5). Continuous treatment of Ob cells with
cortisol caused a time-dependent increase in c-met steady-state mRNA
levels. The effect was first consistently observed after 6 h of
exposure to cortisol at 1 µM and was sustained for 48 h. Treatment
with cortisol increased c-met mRNA levels by 2.5 ± 0.3 (SE; n
= 6-9), 2.5 ± 0.2, and 2.5 ± 0.1 multiples of increase
after 6, 24, and 48 h, respectively, as determined by densitometry
(Fig. 5). The effect of cortisol was dose dependent, and continuous
treatment of Ob cells with cortisol for 24 h at 10 nM, 100 nM, and 1 µM increased c-met transcripts by 2.0 ± 0.4 (SE; n = 4),
3.3 ± 0.9, and 3.6 ± 0.6 multiples of increase,
respectively (Fig. 6).
|
|
To determine possible mechanisms involved in the regulation of HGF/SF
and c-met by glucocorticoids, we examined whether or not the effects
were protein synthesis dependent, and whether they occurred at the
transcriptional or posttranscriptional level. To determine whether the
effect of cortisol was dependent on protein synthesis, Ob cells were
treated with cortisol at 1 µM for 24 h in the presence or absence of
cycloheximide at 3.6 µM, a dose previously shown to block protein
synthesis in osteoblasts (11). Densitometric analysis revealed that, in
an experiment in which cortisol decreased HGF/SF mRNA levels from
control values of 1.00 to 0.6 ± 0.1 (SE; n = 3),
cycloheximide increased HGF/SF mRNA levels to 1.7 ± 0.2 in the
absence, and to 2.0 ± 0.2 in the presence of cortisol. Consequently,
the inhibitory effect of cortisol could not be detected in the presence
of cycloheximide, although the results are difficult to interpret
because of the accumulation of HGF/SF mRNA in cycloheximide-treated
cells. This accumulation or superinduction of transcripts in the
presence of protein synthesis inhibitors is usually attributed to the
inhibition of RNA-degrading enzymes (1, 6). The effect of cortisol on
c-met mRNA levels appeared to be independent of de novo protein
synthesis, because treatment with cycloheximide increased c-met mRNA
levels and enhanced the stimulatory effect of cortisol (Fig.
7). To determine whether cortisol decreased
HGF/SF or increased c-met mRNA levels by changing transcript stability,
cultures of Ob cells were exposed to cortisol at 1 µM for 1-4 h
and then treated with the RNA polymerase II inhibitor DRB for 30 min to
18 h (45). About 75% of Ob cells are viable in the presence of DRB for
24 h, as determined by trypan blue exclusion (Canalis, unpublished
observations). The half-lives of both HGF/SF and c-met mRNA in
transcriptionally arrested osteoblasts were ~3-4 h, and these
were not significantly altered by cortisol (Fig.
8). To determine the effect of cortisol
on the rate of transcription of the HGF/SF and c-met genes, nuclear
run-on assays were performed. Nuclei isolated from Ob cells exposed to
control medium or cortisol at 1 µM for 2, 6, or 24 h revealed that
cortisol did not cause a detectable change in the rate of HGF/SF
transcription but increased the rate of c-met transcription by about
twofold (Fig. 9).
|
|
|
| |
DISCUSSION |
|---|
|
|
|---|
Recent studies have shown that glucocorticoids have significant effects on the number and function of osteoblasts, acting through a variety of mechanisms (8, 13, 44). The present investigation was undertaken to determine whether cortisol regulates the expression of HGF/SF and c-met in osteoblasts. There was a time-related increase in HGF/SF mRNA levels in serum-deprived Ob cell cultures, and this increase was probably due to an accumulation of endogenous growth factors, such as FGF and PDGF, which are synthesized by skeletal cells and can enhance HGF/SF synthesis in osteoblasts (4, 10, 35). Cortisol prevented the time-related increase, causing a relative decrease in HGF/SF mRNA levels in osteoblasts. Cortisol also decreased the induction of HGF/SF transcripts by FGF-2 and PDGF BB in Ob and MC3T3 cells.
Cycloheximide superinduced HGF/SF transcripts in the presence and absence of cortisol, suggesting the inhibition of HGF/SF mRNA-degrading enzymes, which could be induced by cortisol and could be responsible for the decrease in HGF/SF mRNA caused by this steroid (1, 6). Glucocorticoids have been found to induce cytosolic proteins in osteoblasts, which are responsible for changes in the stability of other transcripts, such as those of collagenase 3 (15). Cytosolic proteins are known to bind to AU-rich elements in the RNA, and these sequences often modulate mRNA stability of other genes (20, 43). Although cortisol may regulate RNA-binding proteins in osteoblasts, it is not known whether or not they bind to AU-rich regions of HGF/SF RNA and whether or not they play a role in the inhibitory effect of cortisol on HGF/SF mRNA expression. Furthermore, experiments in transcriptionally blocked Ob cells, by use of the RNA polymerase II inhibitor DRB, revealed that cortisol did not destabilize HGF/SF transcripts (45). It is possible that cortisol destabilizes HGF/SF mRNA, but the effect was not detectable under conditions of transcriptional arrest, which may have suppressed the expression of genes coding for proteins required to regulate HGF/SF transcript stability. Our data are not conclusive, because it was not possible to demonstrate a decrease in the rate of HGF/SF transcription. This could be due to lack of a transcriptional effect or lack of sufficient sensitivity for the detection of an inhibitory effect. Similar difficulties were encountered to prove a transcriptional effect of FGF-2 on HGF/SF expression in osteoblasts and of various cytokines in fibroblasts (4, 41).
The levels of immunoreactive HGF/SF in control and growth factor-induced Ob cells were below the limit of detection with use of currently available assays, so that we could not demonstrate a decrease in HGF/SF levels by cortisol in Ob cells. However, detectable levels of HGF/SF were achieved in MC3T3 cells after induction with FGF-2 and PDGF BB. HGF/SF levels in MC3T3 cells were suppressed by cortisol, revealing that this steroid has the capability to reduce HGF/SF synthesis in osteoblasts. It is not clear why HGF/SF levels can be induced to a greater extent in MC3T3 than in Ob cells, but differences in the level of growth factor expression between Ob and MC3T3 cells are not uncommon (19).
In contrast to the inhibitory effects on HGF/SF expression, cortisol caused a time- and dose-dependent increase in c-met mRNA levels in Ob cells. Cycloheximide superinduced c-met transcripts and had an additive effect to that of cortisol, suggesting the presence of c-met mRNA-degrading enzymes in Ob cell cultures. The effect of cortisol on c-met occurred by transcriptional mechanisms, because cortisol caused no change in the half-life of the transcript in transcriptionally arrested cells and increased the rate of transcription.
In our study, the effects of cortisol on HGF/SF and c-met expression were observed at doses that modify other parameters of metabolic function in Ob cells, suggesting that the effect is physiologically relevant. Glucocorticoids have complex effects on bone remodeling and have a major impact on bone formation. The inhibitory actions of glucocorticoids on bone formation are secondary to a decrease in bone cell replication, to a decrease in bone collagen synthesis, and to an increase in collagenase 3 expression (7, 14, 15). In addition, some of the actions of glucocorticoids are due to modifications in the synthesis of growth factors produced by skeletal cells or alterations in receptor binding or binding proteins (8, 12, 18, 34). The decrease in HGF/SF expression by cortisol may explain selected actions of glucocorticoids in bone, and it may be particularly relevant to the impaired healing of tissues exposed to glucocorticoids.
FGF-2 and PDGF BB stimulate the replication of cells of the osteoblastic lineage and have been implicated in wound and fracture repair; the two growth factors induced HGF/SF expression, an effect attenuated by glucocorticoids (9, 16, 23, 28, 30). This, in conjunction with the known effect of HGF/SF in tissue repair, would suggest a role for HGF/SF in bone repair, which can be opposed by glucocorticoids (26, 38). This effect may serve, in part, to explain the inhibitory actions of glucocorticoids on wound and fracture healing. The induction of c-met by glucocorticoids may be a compensatory mechanism to maintain HGF/SF function in bone. Whereas the induction of c-met by glucocorticoids seems unique to osteoblasts, the decrease in HGF/SF production also occurs in bone marrow stromal cells and fibroblasts (27, 40).
In conclusion, cortisol decreases the synthesis of HGF/SF and increases c-met expression in osteoblasts. These effects may play a role in the inhibitory actions of glucocorticoids on bone formation and repair.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Dr. T. Nakamura for the rat HGF/SF cDNA clone, Dr. C. C. Lee for the mouse c-met cDNA, the Genetics Institute for BMP-2, Sheila Rydziel for technical advice, Cathy Boucher and Deena Durant for technical assistance, and Charlene Gobeli and Karen Berrelli for secretarial help.
| |
FOOTNOTES |
|---|
This study was supported by Grant DK-45227 from the National Institute of Diabetes and Digestive and Kidney Diseases.
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Address for reprint requests and other correspondence: E. Canalis, Department of Research, Saint Francis Hospital and Medical Center, 114 Woodland St., Hartford, CT 06105-1299 (E-mail:ecanalis{at}stfranciscare.org).
Received 13 July 1999; accepted in final form 22 October 1999.
| |
REFERENCES |
|---|
|
|
|---|
1.
Aharon, T.,
and
R. J. Schneider.
Selective destabilization of short-lived mRNAs with the granulocyte-macrophage colony-stimulating factor AU-rich 3' noncoding region is mediated by a cotranslational mechanism.
Mol. Cell. Biol.
13:
1971-1980,
1993
2.
Amata, A.,
K. Matsumoto,
H. Iwanari,
K. Sekiguchi,
S. Kawata,
Y. Matsuzawa,
and
T. Nakamura.
Rapid and sensitive enzyme-linked immunosorbent assay for measurement of HGF in rat and human tissues.
Biomed. Res.
16:
105-114,
1995.
3.
Beer, H. D.,
M. T. Longaker,
and
S. Werner.
Reduced expression of PDGF and PDGF receptors during impaired wound healing.
J. Invest. Dermatol.
109:
132-138,
1997[ISI][Medline].
4.
Blanquaert, F.,
A. M. Delany,
and
E. Canalis.
Fibroblast growth factor-2 induces hepatocyte growth factor/scatter factor expression in osteoblasts.
Endocrinology
140:
1069-1074,
1999
5.
Bottaro, D. P.,
J. S. Rubin,
D. L. Faletto,
A. M. L. Chan,
T. E. Kmiecick,
G. F. Vande Woude,
and
S. A. Aaronson.
Identification of the hepatocyte growth factor receptor has the c-met protooncogene.
Science
251:
802-804,
1991
6.
Brenner, D. A.,
M. O'Hara,
P. Angel,
M. Chojkier,
and
M. Karin.
Prolonged activation of jun and collagenase genes by tumour necrosis factor-alpha.
Nature
337:
661-663,
1989[Medline].
7.
Canalis, E.
Effect of glucocorticoids on type I collagen synthesis, alkaline phosphatase activity and deoxyribonucleic acid content in cultured rat calvariae.
Endocrinology
112:
931-939,
1989[Abstract].
8.
Canalis, E.
Mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis.
J. Clin. Endocrinol. Metab.
81:
3441-3447,
1996[ISI][Medline].
9.
Canalis, E.,
M. Centrella,
and
T. McCarthy.
Effects of fibroblast growth factor on bone formation in vitro.
J. Clin. Invest.
81:
1572-1577,
1988.
10.
Canalis, E.,
J. Pash,
and
S. Varghese.
Skeletal growth factors.
Crit. Rev. Eukaryot. Gene Expr.
3:
155-166,
1993[Medline].
11.
Centrella, M.,
T. L. McCarthy,
and
E. Canalis.
Glucocorticoid regulation of transforming growth factor
1 (TGF-
1) activity and binding in osteoblast-enriched cultures from fetal rat bone.
Mol. Cell. Biol.
11:
4490-4496,
1991
12.
Delany, A. M.,
and
E. Canalis.
Transcriptional repression of insulin-like growth factor I by glucocorticoids in rat bone cells.
Endocrinology
136:
4776-4781,
1995[Abstract].
13.
Delany, A. M.,
Y. Dong,
and
E. Canalis.
Mechanisms of glucocorticoid action in bone cells.
J. Cell. Biochem.
56:
295-302,
1994[ISI][Medline].
14.
Delany, A.,
B. Gabbitas,
and
E. Canalis.
Cortisol down-regulates osteoblast
1 (I) procollagen mRNA by transcriptional and posttranscriptional mechanisms.
J. Cell. Biochem.
57:
488-494,
1995[ISI][Medline].
15.
Delany, A. M.,
J. J. Jeffrey,
S. Rydziel,
and
E. Canalis.
Cortisol increases interstitial collagenase expression in osteoblasts by post-transcriptional mechanisms.
J. Biol. Chem.
270:
26607-26612,
1995
16.
Deuel, T. F.,
and
R. S. Kawahara.
Growth factors and wound healing: platelet-derived growth factor as a model cytokine.
Annu. Rev. Med.
42:
567-584,
1991[ISI][Medline].
17.
Feinberg, A.,
and
B. Vogelstein.
A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity.
Anal. Biochem.
137:
266-267,
1984[ISI][Medline].
18.
Gabbitas, B.,
J. M. Pash,
A. M. Delany,
and
E. Canalis.
Cortisol inhibits the synthesis of insulin-like growth factor binding protein-5 in bone cell cultures by transcriptional mechanisms.
J. Biol. Chem.
271:
9033-9038,
1996
19.
Gangji, V.,
S. Rydziel,
B. Gabbitas,
and
E. Canalis.
Insulin-like growth factor II promoter expression in cultured rodent osteoblasts and adult rat bone.
Endocrinology
139:
2287-2292,
1998
20.
Gillis, P.,
and
J. S. Malter.
The adenosine-uridine binding factor recognizes the AU-rich elements of cytokine, lymphokine, and oncogene mRNAs.
J. Biol. Chem.
266:
3172-3177,
1991
21.
Grano, M.,
F. Galimi,
G. Zambonin,
S. Colucci,
E. Cottone,
A. Z. Zallone,
and
P. M. Comoglio.
Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro.
Proc. Natl. Acad. Sci. USA
93:
7644-7648,
1996
22.
Greenberg, M. E.,
and
E. B. Ziff.
Stimulation of 3T3 cells induces transcription of the c-fos proto-oncogene.
Nature
311:
433-438,
1984[Medline].
23.
Hock, J. M.,
and
E. Canalis.
Platelet-derived growth factor enhances bone cell replication but not differentiated function of osteoblasts.
Endocrinology
134:
1423-1428,
1994[Abstract].
24.
Hock, J. M.,
M. Centrella,
and
E. Canalis.
Insulin-like growth factor I (IGF-I) has independent effects on bone matrix formation and cell replication.
Endocrinology
122:
254-260,
1988[Abstract].
25.
Lee, C.,
and
K. M. Amata.
Identification of a novel type of alternative splicing of a tyrosine kinase receptor. Juxtamembrane deletion of the c-met protein kinase C serine phosphorylation regulatory site.
J. Biol. Chem.
269:
19457-19461,
1994
26.
Matsumoto, K.,
and
T. Nakamura.
Emerging multipotent aspects of hepatocyte growth factor.
J. Biochem.
119:
591-600,
1996
27.
Matsumoto, K.,
H. Tajima,
H. Okazaki,
and
T. Nakamura.
Negative regulation of hepatocyte growth factor gene expression in human lung fibroblasts and leukemic cells by transforming growth factor-
1 and glucocorticoids.
J. Biol. Chem.
267:
24917-24920,
1992
28.
Mayahara, H.,
T. Ito,
H. Nagai,
H. Miyajima,
R. Tsukuda,
S. Taketomi,
J. Mizoguchi,
and
K. Kato.
In vivo stimulation of endosteal bone formation by basic fibroblast growth factor in rats.
Growth Factors
9:
73-80,
1993[ISI][Medline].
29.
McCarthy, T. L.,
M. Centrella,
and
E. Canalis.
Further biochemical and molecular characterization of primary rat parietal bone cell cultures.
J. Bone Miner. Res.
3:
401-408,
1988[ISI][Medline].
30.
Mitlak, B. H.,
R. D. Finkelman,
E. L. Hill,
J. Li,
B. Martin,
T. Smith,
M. D'Andrea,
H. N. Antoniades,
and
S. E. Lynch.
The effect of systemically administered PDGF-BB on the rodent skeleton.
J. Bone Miner. Res.
11:
238-247,
1996[ISI][Medline].
31.
Nakamura, T.,
T. Nishizawa,
M. Hagiya,
T. Seki,
M. Shimonishi,
A. Sugimura,
K. Tashiro,
and
S. Shimizu.
Molecular cloning and expression of human hepatocyte growth factor.
Nature
342:
440-443,
1989[Medline].
32.
Naldini, L.,
E. Vigna,
R. Narisiham,
G. Gaudino,
R. Zarnegar,
G. Michalopoulos,
and
P. M. Comoglio.
Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET.
Oncogene
6:
501-504,
1991[ISI][Medline].
33.
Okano, J. I.,
G. Shiota,
and
H. Kawasaki.
Protective action of hepatocytes growth factor for acute liver injury caused by D-galactosamine in transgenic mice.
Hepatology
26:
1241-1249,
1997[ISI][Medline].
34.
Rydziel, S.,
and
E. Canalis.
Cortisol expresses insulin-like growth factor II receptor transcription in skeletal cell cultures.
Endocrinology
136:
4254-4260,
1995[Abstract].
35.
Rydziel, S.,
and
E. Canalis.
Expression and growth factor regulation of platelet-derived growth factor B transcripts in primary osteoblast cell cultures.
Endocrinology
137:
4115-4119,
1996[Abstract].
36.
Schmidt, C.,
F. Bladt,
S. Goedecke,
V. Brinkmann,
W. Zschiesche,
M. Sharpe,
E. Gheraradi,
and
C. Birchmeier.
Scatter factor/hepatocyte growth factor is essential for liver development.
Nature
373:
699-702,
1995[Medline].
37.
Sokal, R. R.,
and
F. J. Rohlf.
Biometry (2nd ed.). San Francisco: Freeman, 1981.
38.
Strain, A. J.
Hepatocyte growth factor: another ubiquitous cytokine.
J. Endocrinol.
137:
1-5,
1993
39.
Sudo, H.,
H. A. Kodama,
Y. Amagai,
S. Yamamoto,
and
S. Kasai.
In vitro differentiation and calcification in a new cell line derived from newborn mouse calvaria.
J. Cell. Biol.
96:
191-198,
1983
40.
Takai, K.,
J. Hara,
K. Matsumoto,
G. Hosoi,
Y. Osugi,
A. Tawa,
S. Okada,
and
T. Nakamura.
Hepatocyte growth factor is constitutively produced by human bone marrow stromal cells and indirectly promotes hematopoiesis.
Blood
89:
1560-1565,
1997
41.
Tamura, M.,
N. Arakaki,
H. Tsubouchi,
H. Takada,
and
Y. Daikuhara.
Enhancement of human hepatocyte growth factor production by interleukin-1
and -1
and tumor necrosis factor-
by fibroblasts in culture.
J. Biol. Chem.
268:
8140-8145,
1993
42.
Uehara, Y.,
O. Minowa,
C. Mori,
K. Shiota,
J. Kuno,
T. Noda,
and
N. Kitamura.
Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter.
Nature
373:
702-705,
1995[Medline].
43.
Vakalopoulou, E.,
J. Schaack,
and
T. Shenk.
A 32-kilodalton protein binds to AU-rich domains in the untranslated regions of rapidly degraded mRNAs.
Mol. Cell. Biol.
11:
3355-3364,
1991
44.
Weinstein, R. S.,
R. L. Jilka,
A. M. Parfitt,
and
S. C. Manolagas.
Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids.
J. Clin. Invest.
102:
274-282,
1998[ISI][Medline].
45.
Zandomeni, R.,
D. Bunick,
S. Ackerman,
B. Mittleman,
and
R. Weinmann.
Mechanism of action of DRB. Effect on specific in vitro initiation of transcription.
J. Mol. Biol.
167:
561-574,
1983[ISI][Medline].
This article has been cited by other articles:
![]() |
J. O. Hollinger, C. E. Hart, S. N. Hirsch, S. Lynch, and G. E. Friedlaender Recombinant Human Platelet-Derived Growth Factor: Biology and Clinical Applications J. Bone Joint Surg. Am., February 1, 2008; 90(Supplement_1): 48 - 54. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Patane, S. Avnet, N. Coltella, B. Costa, S. Sponza, M. Olivero, E. Vigna, L. Naldini, N. Baldini, R. Ferracini, et al. MET Overexpression Turns Human Primary Osteoblasts into Osteosarcomas. Cancer Res., May 1, 2006; 66(9): 4750 - 4757. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Chattopadhyay, R. J. MacLeod, J. Tfelt-Hansen, and E. M. Brown 1alpha ,25(OH)2-vitamin D3 inhibits HGF synthesis and secretion from MG-63 human osteosarcoma cells Am J Physiol Endocrinol Metab, January 1, 2003; 284(1): E219 - E227. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |